ASKA Pharmaceutical Holdings Co., Ltd. (JP:4886)
:4886
Want to see JP:4886 full AI Analyst Report?
4886 Stock Chart & Stats
¥2038.00
-¥23.00(-1.13%)
At close: 4:00 PM EST
¥2038.00
-¥23.00(-1.13%)
Day’s Range― - ―
52-Week Range¥1,920.00 - ¥3,045.00
Previous CloseN/A
Volume48.10K
Average Volume (3M)49.10K
Market Cap
¥61.05B
Enterprise Value¥58.68B
Total Cash (Recent Filing)¥7.23B
Total Debt (Recent Filing)¥13.77B
Price to Earnings (P/E)12.2
Beta0.52
Next Earnings
Aug 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.52%
Share Statistics
EPS (TTM)178.85
Shares Outstanding28,763,199
10 Day Avg. Volume37,820
30 Day Avg. Volume49,100
Financial Highlights & Ratios
PEG Ratio1.99
Price to Book (P/B)0.96
Price to Sales (P/S)0.94
P/FCF Ratio17.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)197.8
Revenue Forecast (FY)¥71.06B
Bulls Say, Bears Say
Bulls Say
Strengthened Balance SheetMeaningful debt reduction alongside substantial equity growth materially lowers financial risk and increases strategic optionality. This durable improvement supports funding for R&D, capacity investments or M&A without excessive leverage, and strengthens the firm's ability to withstand reimbursement or market shocks over the medium term.
Consistent Revenue GrowthSteady multi-year top-line growth indicates enduring demand for the company’s portfolio and provides a stable base for operating scale. Persistent revenue expansion supports margin sustainability, funds pipeline progress and commercial efforts, and reduces reliance on one-off gains, making business outcomes more predictable over several quarters.
Integrated Development-to-commercial ModelOwning end-to-end capabilities—from development through domestic commercialization—enables faster launches, closer lifecycle management and higher capture of product margins. This integrated model supports durable competitive advantages in market access, pricing negotiations and execution versus firms relying solely on licensing or external commercialization.
Bears Say
Volatile Cash GenerationLarge swings in operating cash flow and a negative free cash flow year reduce predictability of internal funding for R&D, capex and shareholder returns. Even with a rebound, such variability suggests working-capital or investment timing risk that can constrain strategic flexibility and stress liquidity in adverse periods.
Variable Profitability MetricsFluctuating returns on equity and uneven net income across recent years indicate inconsistent profit efficiency and operating leverage. This variability complicates forecasting of margins and shareholder returns, and may reflect sensitivity to product mix, pricing or cost swings rather than stable, repeatable earnings power.
Exposure To Reimbursement/regulatory RiskA business model tied to Japan’s reimbursement-driven pricing leaves revenues and margins vulnerable to policy changes. Limited geographic diversification heightens exposure: regulatory or pricing revisions can materially compress cash flows and profitability, making long-term planning and return assumptions more uncertain.
ASKA Pharmaceutical Holdings Co., Ltd. News
4886 FAQ
What was ASKA Pharmaceutical Holdings Co., Ltd.’s price range in the past 12 months?
ASKA Pharmaceutical Holdings Co., Ltd. lowest stock price was ¥1920.00 and its highest was ¥3045.00 in the past 12 months.
What is ASKA Pharmaceutical Holdings Co., Ltd.’s market cap?
ASKA Pharmaceutical Holdings Co., Ltd.’s market cap is ¥61.05B.
When is ASKA Pharmaceutical Holdings Co., Ltd.’s upcoming earnings report date?
ASKA Pharmaceutical Holdings Co., Ltd.’s upcoming earnings report date is Aug 04, 2026 which is in 44 days.
How were ASKA Pharmaceutical Holdings Co., Ltd.’s earnings last quarter?
ASKA Pharmaceutical Holdings Co., Ltd. released its earnings results on May 07, 2026. The company reported ¥53.53 earnings per share for the quarter, beating the consensus estimate of N/A by ¥53.53.
Is ASKA Pharmaceutical Holdings Co., Ltd. overvalued?
According to Wall Street analysts ASKA Pharmaceutical Holdings Co., Ltd.’s price is currently Overvalued.
Does ASKA Pharmaceutical Holdings Co., Ltd. pay dividends?
ASKA Pharmaceutical Holdings Co., Ltd. pays a Semiannually dividend of ¥32 which represents an annual dividend yield of 2.52%. See more information on ASKA Pharmaceutical Holdings Co., Ltd. dividends here
What is ASKA Pharmaceutical Holdings Co., Ltd.’s EPS estimate?
ASKA Pharmaceutical Holdings Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ASKA Pharmaceutical Holdings Co., Ltd. have?
ASKA Pharmaceutical Holdings Co., Ltd. has 28,763,199 shares outstanding.
What happened to ASKA Pharmaceutical Holdings Co., Ltd.’s price movement after its last earnings report?
ASKA Pharmaceutical Holdings Co., Ltd. reported an EPS of ¥53.53 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.553%.
Which hedge fund is a major shareholder of ASKA Pharmaceutical Holdings Co., Ltd.?
Currently, no hedge funds are holding shares in JP:4886
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
ASKA Pharmaceutical Holdings Co., Ltd.
ASKA Pharmaceutical Holdings Co.,Ltd. is a Japanese enterprise that operates through its subsidiaries in three primary areas: pharmaceuticals, animal healthcare, and hormone testing services. The company's pharmaceutical division is dedicated to the research, development, production, and commercialization of medications, with a specific focus on endocrinology, obstetrics and gynecology, and urology. Within its animal health segment, ASKA manufactures, sells, imports, and exports a broad spectrum of veterinary products, such as medicines, medical equipment, animal feed and supplements, laboratory reagents, agricultural chemicals, industrial chemicals, hygiene products, and food items along with their raw materials. Beyond these activities, the company also performs clinical and biological testing and offers medical devices. Founded in 1920, ASKA Pharmaceutical Holdings Co.,Ltd. is headquartered in Tokyo, Japan.
Technical Analysis
Kaken Pharmaceutical Co
―
Fuji Pharma Co., Ltd.
―
Mochida Pharmaceutical Co., Ltd.
―
KYORIN Pharmaceutical Co.,Ltd.
―
Daito Pharmaceutical Co., Ltd.
―
Options Prices
Currently, No data available
---